Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120,138,422
-
Total 13F shares
-
59,305,828
-
Share change
-
+10,242,324
-
Total reported value
-
$1,133,330,532
-
Put/Call ratio
-
8.1%
-
Price per share
-
$19.11
-
Number of holders
-
135
-
Value change
-
+$193,854,925
-
Number of buys
-
101
-
Number of sells
-
27
Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q3 2022
As of 30 Sep 2022,
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) was held by
135 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
59,305,828 shares.
The largest 10 holders included
FMR LLC, Frazier Life Sciences Management, L.P., BlackRock Inc., Point72 Asset Management, L.P., Bain Capital Life Sciences Investors, LLC, ORBIMED ADVISORS LLC, STATE STREET CORP, VANGUARD GROUP INC, PICTET ASSET MANAGEMENT SA, and Logos Global Management LP.
This page lists
137
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.